Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Guidant

This article was originally published in The Gray Sheet

Executive Summary

Enrollment in the firm's 1,042-patient, 70-center DELIVER trial to evaluate effectiveness of the paclitaxel-coated Multi-Link Penta stent compared to an uncoated version is expected to begin in mid-November following submission of an investigational device exemption application, announced Oct. 8. Nine-month follow-up is expected by the fourth quarter of 2002. Separately, Guidant announces CE mark approval for the Insignia pacemaker line, European launch of the Acculink carotid stent system and worldwide launch of the second-generation Viatrac 14 Plus peripheral dilatation catheter for treatment of blockages of peripheral arteries
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT015541

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel